A study to know the effects of a chemotherapy medicine named Gemcitabine plus Docetaxel combination in patients of recurrent or advanced soft tissue sarcoma
Not Applicable
- Conditions
- Health Condition 1: null- Recurrent of metastatic soft tissue sarcoma
- Registration Number
- CTRI/2018/08/015291
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Age 18-60 years
2) Histologically/Cytologically proven metastatic/advanced(recurrent) STS
3) Previously treated with at least one first-line regimen in neo-adjuvant or advanced or metastatic setting and either progressed on chemotherapy or recurred to an advanced stage, after failure of/intolerance to first line systemic chemotherapy
4)Received at least 3 cycles of Gemcitabine-Docetaxel combination as second line therapy in the advanced(recurrent) or metastatic settling
Exclusion Criteria
Incomplete data on EMR or case records
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the outcomes of gemcitabine-docetaxel combination as second-line systemic chemotherapy in patients of recurrent or metastatic soft tissue sarcomasTimepoint: Post 3 cycles of Gemcitabine plus Docetaxel
- Secondary Outcome Measures
Name Time Method To study the toxicity profile, tolerance, progression free <br/ ><br>Survival(PFS), and overall survival(OS) in the study population <br/ ><br>Timepoint: Post 3 cycles of Gemcitabine plus Docetaxel